The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

FDA grants RMAT designation to CD30 CAR-T Cell Therapy in hodgkin lymphoma indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FDA has granted Tessa Therapeutics investigational CD30-directed autologous chimeric antigen receptor T cell therapy Regenerative Medicine Advanced Therapy for relapsed or refractory CD30-positive classical Hodgkin lymphoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account